Structural basis for vitamin D receptor agonism by novel non-secosteroidal ligands  by Asano, Lisa et al.
FEBS Letters 587 (2013) 957–963journal homepage: www.FEBSLetters .orgStructural basis for vitamin D receptor agonism by novel
non-secosteroidal ligands0014-5793/$36.00  2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.febslet.2013.02.028
Abbreviations: VDR, vitamin D receptor; 1,25(OH)2D3, 1a,25-dihydroxyvitamin
D3; CoA, coactivator; LBD, ligand binding domain; LBP, ligand binding pocket
⇑ Corresponding author at: Graduate School of Pharmaceutical Sciences, Univer-
sity of Tokyo, Hongo, Bunkyo-ku, Tokyo 113-0033, Japan. Fax: +81 03 5841 4891.
E-mail address: shimizu@mol.f.u-tokyo.ac.jp (T. Shimizu).Lisa Asano a,d, Ichiaki Ito b, Naoyuki Kuwabara a,d, Tsuyoshi Waku a, Junn Yanagisawa b,
Hiroyuki Miyachi c, Toshiyuki Shimizu a,d,⇑
aGraduate School of Pharmaceutical Sciences, University of Tokyo, Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
bGraduate School of Life and Environmental Sciences/Life Science Center of Tsukuba Advanced Research Alliance, University of Tsukuba, Tsukuba Science City, Ibaraki 305-8577, Japan
cGraduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, 1-1-1, Tsushima-Naka, Kita-ku, Okayama 700-8530, Japan
dRIKEN SPring-8 Center, Kouto 1-1-1, Sayo, Hyogo 679-5148, Japan
a r t i c l e i n f o a b s t r a c tArticle history:
Received 1 November 2012
Revised 23 January 2013
Accepted 15 February 2013
Available online 24 February 2013
Edited by Laszlo Nagy
Keywords:
Vitamin D receptor
Non-secosteroidal ligand
Agonism
Crystal structureNon-secosteroidal ligands for vitamin D receptor (VDR) have been developed for the agonist with
non-calcemic proﬁles. Here, we provide the structural mechanism of VDR agonism by novel non-
secosteroidal ligands. All ligands had the similar efﬁcacy, while two had the higher potency. Crystal-
lographic analyses revealed that all ligands interacted with helix H10 and the loop between helices
H6 and H7 in a similar manner, but also that the two ligands with higher potency had different
interaction modes. This study suggests that distinct ligand potency depend upon differences in
the formation and rearrangement of hydrogen-bond networks induced by each ligand.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The nuclear receptor, vitamin D receptor (VDR), is a ligand-
dependent transcription factor in response to the active form of
vitamin D, 1a,25-dihydroxyvitamin D3 [1,25(OH)2D3] [1,2]. Gener-
ally, a nuclear receptor is activated when the ligand interacts with
Activation Function-2 (AF-2) helix H12 within the ligand binding
domain (LBD). This, in turn, results in the recruitment of the coac-
tivator (CoA) onto the LBD surface, which lies in close proximity to
AF-2 [3]. VDR regulates calcium homeostasis, cell proliferation/dif-
ferentiation, and the immune response, and its dysfunction causes
osteoporosis, cancer, and inﬂammation. Therefore, VDR-targeting
drugs have been used for the therapeutic treatment of these dis-
eases [4–6].
To date, a lot of efforts have been expended to develop novel
VDR ligands [7]. These ligands can be classiﬁed into two groups,
‘‘secosteroid’’ and ‘‘non-secosteroid’’; the former has a steroid
backbone, and the later has not. Although almost all known VDRligands are secosteroids, they cause hypercalcemia. Moreover,
structural complexity of secosteroids results in synthetic inconve-
nience [8]. On the other hand, non-secosteroids was identiﬁed as
compounds to avoid these disadvantages [9–12]. This non-secos-
teroidal vitamin D3 analog mimics various activities of a well-
known secosteroidal ligand, 1,25(OH)2D3 in vitro and in vivo, such
as VDR binding, VDR-dependent transcriptional activation, inhibi-
tion of proliferation and differentiation [9]. New and more potent
non-secosteroids that do not cause hypercalcemia are urgently
awaited.
Here, we developed four novel non-secosteroids, TTYN-7, -8, -
11, and -12, to help understand the structural mechanism underly-
ing VDR activation by non-secosteroids. Transcriptional assays
using human VDR revealed that TTYN-8/11 acted as a more potent
VDR ligand than TTYN-7/12 although all of the TTYNs had similar
efﬁcacy to the known ligand, 1,25(OH)2D3. We also determined
the crystal structure of rat VDR LBD (rVDR LBD) bound to a TTYN
and a CoA peptide. All TTYNs formed the same hydrogen bonds
with the H6–7 loop and H10, but the diol moieties of these ligands
changed the conformation of the VDR, resulting in different hydro-
gen-bond networks depending on the potency of the ligand. Fur-
thermore, we performed mutation analyses of the residues
involved in the interactions. This study shows that the efﬁcacy of
the novel TTYNs may depend on direct interactions with H6–7 loop
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formation and rearrangement of interaction networks between
helices H3 and H5.
2. Methods
2.1. Protein puriﬁcation and crystallization
The rat VDR LBD (residues 116–423) lacking the ﬂexible inser-
tion region (residues 165–211) was overexpressed as a His-tagged
peptide in Escherichia coli BL21(DE3). Puriﬁcation procedures in-
cluded Ni-NTA afﬁnity chromatography. After tag removal by pre-
cision protease, the protein was further puriﬁed by gel ﬁltration on
a Superdex200 column. Crystals of rVDR LBD in complex with a
TTYN and a synthetic CoA peptide containing the LXXLL sequence
(hSRC1 residues 625–637) were obtained as described previously
[13].
2.2. Data collection and model reﬁnement
The diffraction data were collected at BL32XU or BL41XU at
SPring-8 (Harima, Japan). All data were processed with HKL2000
[14], and further analyses were carried out using the CCP4 suite
[15]. The structures were solved by the molecular replacement
method by using the program Molrep [16] and the coordinates of
rVDR LBD (PDB ID: 1RK3) as a search model. The structural models
were reﬁned with stepwise cycles of manual model-building using
program COOT [17] and restrained reﬁnement was performed
using REFMAC [18] until the R factor converged. The Ramachan-
dran plots of the ﬁnal models showed that all of the amino acid
residues were in the most favored and allowed region. The crystal-
lographic data and reﬁnement statistics are summarized in Table 1.
Coordinates for all complexes have been deposited in the Protein
Data Bank (PDB), with the accession codes 3W0G (TTYN-7 bound),
3W0J (TTYN-8 bound), 3W0I (TTYN-11 bound), and 3W0H (TTYN-
12 bound).Table 1
Data collection and reﬁnement statistics.
TTYN7 TTYN8 TTYN11 TTYN12
Data collection
Wavelength 1.0000 1.0000 1.0000 1.0000
Space group C2 C2 C2 C2
Unit cell parameters
a (Å) 154.3 154.0 154.1 124.6
b (Å) 42.0 42.4 42.4 45.1
c (Å) 42.1 42.1 42.4 47.2
b () 94.9 94.9 94.9 100.4
Resolution range
(Å)
50.0–1.94 50.0–1.80 50.0–1.90 50.0–1.80
(2.03–1.94)a (1.86–
1.80)
(1.98–
1.90)
(1.86–
1.80)
Completeness (%) 100.0
(100.0)
97.3 (99.1) 99.4 (100) 99.3 (99.7)
Redundancy 3.5(3.0) 3.8(3.8) 3.7(3.8) 3.7(3.8)
Rmerge
b (%) 4.7 (54.6) 5.0 (34.6) 5.1 (30.7) 6.5 (38.4)
Average I/r (I) 10.0 (3.5) 10.0 (3.3) 39.6 (5.0) 35.1 (7.8)
Reﬁnement
Rc (%)/Rfreed (%) 21.4/25.8 22.3/25.7 19.7/25.0 18.9/23.0
Rms deviations
Bond length (Å) 0.011 0.013 0.011 0.011
Bond angles () 1.27 1.28 1.43 1.40
a Values in parentheses are for the shell with the highest resolution.
b Rmerge (I) = R|I  <I>|/RI, where I is the diffraction intensity.
c R = R|Fo  Fc|/RFo, where Fo and Fc are the observed and calculated structure
amplitudes, respectively.
d Rfree is an R value for a 5% subset of all reﬂections, but was not used in the
reﬁnement.2.3. Cell culture and transcriptional assay
HEK293 cells were maintained in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum
(FBS). Three tandem VDR response elements were subcloned into
a pGL3-Basic reporter plasmid (VDRE-Luc). The VDRE-Luc plasmid
was cotransfected into 293 cells with an expression vector encod-
ing wild-type (WT) or mutant hVDR. The RL-TK plasmid vector was
also cotransfected as an internal control. Transfection was per-
formed with PerFectin Transfection Reagent (Gene Therapy Sys-
tems) according to the manufacturer’s protocols. Twenty-four
hours after transfection, the culture medium was replaced with
fresh phenol red-free DMEM containing 0.2% charcoal-stripped
FBS, and the ligands were added to the cells. After a further 24 h
incubation, luciferase assays were performed with cell extracts
according to the manufacturer’s protocol (Promega). Transcrip-
tional activities are shown with ±S.D. (n = 3–4). To calculate the
estimated EC50 values of TTYNs, sigmoidal dose–response curves
were ﬁtted to the non-linear logistic function of the GraphPad
Prism 4 (GraphPad Software Inc., San Diego, CA). The minimum
and maximum transcriptional activities were constrained to the
value obtained for 1,25(OH)2D3 in the same experiment, based
on the previously reported [19,20]. R2 values of ﬁtting models for
1,25(OH)2D3, TTYN-7, -8, -11, and -12 are 0.9816, 0.9713, 0.9791,
0.9772, and 0.9513, respectively.
Immunoblot analyses of the cell lysates revealed that the
expression and stability of each mutant was similar to that of the
WT (data not shown), indicating that the mutations introduced
into the proteins did not affect their structural integrity.
3. Results and discussion
3.1. Efﬁcacy and potency of the novel non-secosteroidal VDR ligands
(TTYNs)
We synthesized new non-secosterodal ligands (TTYN series) by
modifying the bulkiness around the bis-phenyl group (Fig. S1),
which plays an important role in ligand interaction with the hydro-
phobic pocket formed by Leu226, Ile267, Met268, Trp282, and
Val296. The chemical structures of each TTYN consist of three
groups; a diol, a bis-phenyl, and other chemical groups. Hereafter,
these groups will be referred to as right, middle, and left groups,
respectively (Fig. 1A). The left and right groups are identical among
the ligands, but the middle group is different.
Pharmacologically, the ability of each ligand to activate the nu-
clear receptor relies on two functions, potency and efﬁcacy. The
potency is a function of the amount of ligand required for the spe-
ciﬁc effect to occur. It is measured simply as the inverse of the EC50
for that ligand. By contrast, efﬁcacy measures the maximum
strength of the effect itself, at saturating ligand concentrations.
To investigate potency and efﬁcacy of TTYNs for inducing VDR
activity, we performed a transcriptional assay using the VDRE_Luc
reporter. TTYN-7/12 had lower potencies than TTYN-8/11 or
1,25(OH)2D3 (Fig. 1B). On the other hand, the dose–response curves
of TTYNs did not reach a plateau, because ligand concentrations
greater than 10 lM resulted in cellular damage. Thus, for the vali-
dation of the efﬁcacy of each TTYN, we assumed that all TTYNs had
a similar minimum (Emin) and maximum (Emax) VDR activities to
that of 1,25(OH)2D3, and determined EC50 value of each ligand by
non-linear regression using constrained logistic dose–response
mode, as reported previously [19,20] (See Section 2 for details).
Consequently, we estimated EC50values of 5.98 pM, 1.89 lM,
175 nM, 749 nM and 6.84 lM for TTYN-7, -8, -11, and -12, respec-
tively. We also conﬁrmed that R2 values for all ﬁtting models were
higher than 0.95. Therefore, these results indicated that ﬁtting
model and EC50 value of each ligand were appropriately estimated.
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Fig. 1. Transcriptional validation of the novel non-secosteroidal VDR ligands (TTYNs). (A) Chemical structures of the TTYNs. Diol, bis-phenyl, and other chemical groups are
represented as right (blue), middle (green), and left groups (red), respectively. (B) Dose–response curves of TTYNs for hVDR-mediated transcription. 1,25(OH)2D3 (black),
TTYN-7 (yellow), TTYN-8 (orange), TTYN-11 (green), and TTYN-12 (magenta) were added at the indicated concentrations. (C) Maximum activities of TTYNs for hVDR-
mediated transcription at estimated EC50 concentrations. 1,25(OH)2D3 (black), TTYN-7 (yellow), TTYN-8 (orange), TTYN-11 (green), and TTYN-12 (magenta) were added at
5.98 pM, 1.89 lM, 175 nM, 749 nM and 6.84 lM, respectively.
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1,25(OH)2D3 at the estimated EC50 value (Fig. 1C). Taken together,
these results show that TTYN-7/12 were low potency ligands,
whereas TTYN-8/11 were high potency ligands, although all the li-
gands exhibit similar efﬁcacy.
3.2. Overall structures of the four TTYN/VDR complexes
The structures of rVDR LBD bound to each TTYN and a CoA pep-
tide were reﬁned at 1.8–2.0 Å resolution (Table 1). All structures
display one clear conformation with a single ligand conformer in
the ligand binding pocket (LBP) comprised by helices H3, H5, H7
and H11. The helix H12 was in the agonist position and tightly
packed toward the LBP, and the CoA peptide bound to the surface
formed by the residues from helices H3, H4 and H12 (Fig. 2). The
overall structures of the rVDR LBD complexed with the compounds
are essentially the same as that of rVDR LBD bound to 1,25(OH)2D3.
In fact, the main-chain atoms of each complex could be superim-
posed on those of the 1,25(OH)2D3 complex (PDB ID 1RK3) with
root mean square deviations (RMSD) ranging from 0.3 to 0.5 Å.
All TTYNs embeds in the ligand-binding pocket of VDR in the same
position as 1,25(OH)2D3. These ligands are superimposed well with
1,25(OH)2D3 (Fig. S2A).3.3. Different hydrogen-bond networks between TTYN and rVDR LBD
Generally, VDR ligands are recognized via a variety of hydrogen
bonds and hydrophobic contacts. Especially, Tyr143, Ser233,
Arg270, Ser274, His301, and His393 in rVDR (Tyr147, Ser237,
Arg274, Ser278, His305, and His397 in hVDR) are important for
interactions between the VDR and 1,25(OH)2D3 [21]. Though
hydrogen bond network is partially different between
1,25(OH)2D3 and TTYNs, both ligands are recognized in a similar
manner. In fact, three hydroxyl groups, 1-OH, 2-OH and 20-OH, of
TTYNs play the same roles as the 3-OH, 1-OH, and 25-OH of
1,25(OH)2D3, respectively (Fig. S2B).
His301 on H6-H7 loop and His393 on helix H10, both of which
are crucial for anchoring the ligand, form direct hydrogen bonds
with the left group of each of the novel TTYNs described here,
and this was also the case for 1,25(OH)2D3 and all of the previously
reported highly potent non-secoeteroidal VDR ligands [22,23]
(Fig. 3A).
However we observed signiﬁcant differences in the hydrogen
networks formed with the right group that depended on the po-
tency of each TTYN. The 2-OH group within the right group of
the high potency TTYN-8/11 ligands directly interacts with
Ser233 and Arg270. By contrast, the 2-OH group of the low potency
H3
H12
H11
CoA
H7H5
C
N
TTYN-7 TTYN-8
TTYN-11 TTYN-12
H6
H10
Fig. 2. Crystal structures of rVDR LBD complexed to each of the four TTYNs and a coactivator. Overall structures of the four complexes are represented with the 2|Fo|  |Fc|
electron density map of each ligand (contoured at 1r). TTYN-7, -8, -11, and -12 are colored yellow, orange, green, and magenta, respectively. rVDR LBD and CoA peptide are
gray and cyan, respectively. For clarity, only helices described in this study are shown.
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idues via a water molecule. It should be noted that the non-secos-
teroidal ligand, YR301, which exhibits high efﬁcacy and potency, is
recognized in a manner similar to that of TTYN-8/11 [22]. There-
fore, the direct interaction with Arg270 and Ser233 may be closely
related to potency.
On the other hand, the 1-OH within the right groups of the
TTYNs recognizes VDR in a variety of ways. The high potency
TTYN-8 ligand makes a water-mediated hydrogen bond with
Tyr143 and Ser274, but the high potency TTYN-11 ligand forms a
hydrogen bond with Asp144 via a water molecule. The low potency
TTYN-7/12 ligands form direct hydrogen bonds with Tyr143 and
Ser274 (Fig. 3A), and YR301 makes direct hydrogen bonds with
Arg270 and forms water-mediated hydrogen bonds to Tyr232
and Asp144.Considering that all TTYNs had similar efﬁcacies but different
potencies (Fig. 1C), these results suggest that hydrogen-bond net-
works formed with the left group and right group of each TTYN
might be the most crucial determinants of ligand efﬁcacy and po-
tency, respectively.
Furthermore, we found that Ser271 forms a double conformer
in the structure of the TTYN-12 complex (Fig. 3B). TTYN-12 pos-
sesses the largest middle group among all ligands used in this
study (Fig. 1A), and this bulky group is very close to Ser271
(approximately 2.9 Å), suggesting that the double conformer of
Ser271 might result from steric hindrance between Ser271 and
TTYN-12. Interestingly, Ser271 directly interacts with Met268 on
helix H5 and Gln313 on helix H7 in the TTYN-12 complex
(Fig. 3B, right panel), which had the lowest potency. These two res-
idues directly interact with each other in other TTYN complexes
Ser233 Arg270
Tyr143
Ser274
His301
His393
Ser233 Arg270
Tyr143
Ser274
His301
His393
Ser233
Arg270
His301
His393
Ser233 Arg270
Tyr143
Ser274
His301
His393
Tyr232
Asp144
8-NYTT7-NYTT
TTYN-11
B
A
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TTYN-8 TTYN-12
Fig. 3. Structural descriptions of TTYN-binding modes to rVDR LBD complexes. (A) Interactions of left and right groups of each TTYN with rVDR LBD. Hydrogen bonds are
shown as blue dashed lines. TTYN-7, -8, -11, and -12 are colored yellow, orange, green, and magenta, respectively. Water molecules are shown as cyan spheres. (B) The Ser271
conformation in the VDR complex with the high potency TTYN-8 ligand and with the low potency TTYN-12 ligand. Single and double conformers of Ser271 in VDR complexes
with TTYN-8 and -12 are shown with 2|Fo|  |Fc| electron density maps (contoured at 1r) in left and right panels, respectively. Black dashed lines represent hydrogen bonds
with Met268 on helix H5, Gln313 on helix H7, and/or each ligand.
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that the ligand potency is also partially regulated via a conforma-
tional alteration of Ser271 caused by ligand-speciﬁc rearrange-
ments of the intramolecular interaction between helices H5 and
H7.
The middle group of TTYN-8/11/12 ﬁlls the hydrophobic pocket,
but the middle group of TTYN7 is not sufﬁcient to ﬁll the pocket
and is shifted toward Met268 by 0.9 Å compared to TTYN12
(Fig. S3). These characteristics of the ligands are predicted to have
effects on ligand binding mode to the ligand binding pocket, result-
ing in differences in transcriptional activity; however, this conjec-
ture will need to be veriﬁed in a future study.
3.4. Mutational effects of TTYN–LBD interactions on VDR-mediated
transcription
To investigate whether the observed ligand–protein interac-
tions are crucial for VDR activation by each TTYN, we introduced
four related point mutations into hVDR and then validated the li-
gand-induced transcriptional activities of the mutants (Fig. 4A).
S237A and R274A hVDR (S233A and R270A in rVDR) could not
be activated by the low potency TTYN-7/12 ligands as well as the
high potency TTYN-8/11 ligands. On the other hand, the S278A
hVDR mutation (S274A in rVDR) did not affect the transcriptional
activation induced by any of the TTYNs. These results are in good
agreement with the structural insights, which showed that the for-
mation of interaction networks with Ser233 and Arg270, but notSer274, acts as the main regulator of ligand potency for VDR acti-
vation by all TTYNs (Fig. 3A). In TTYN7, 8 and 11, S275A hVDR
(S271A rVDR) resulted in a moderate reduction in transcriptional
activity, whereas the activity was retained in TTYN12. The muta-
tional analysis suggests that because of the double conformer in
TTYN12, Ser271 makes little contribution to ligand-dependent sta-
bilization by the hydrogen bond between helix H5 and helix H7,
resulting in low potency for this ligand.
3.5. Comparison with other non-secosteroidal ligands
Recently, several non-secosteroidal ligands were developed
from bis- or tris-aromatic derivatives [24]. These ligands, called
CDs, possess the nanomolar-potency for VDR activation similar to
1,25(OH)2D3. TTYNs and CDs share the same position in VDR.
Though the backbone of CDs is different from that of TTYNs, they
have in common three hydroxyl groups and their conformations
in VDR are very similar. Unlike 1,25(OH)2D3, it is suggested that
CDs directly change the conformation of helix H6, and then indi-
rectly push the loop between helices H1 and H3 to regulate VDR
activity based on structural comparisons between VDR in complex
with CDs and 1,25(OH)2D3. To compare CDs with TTYNs structures,
these structures were superimposed and displacements of Ca
atoms around helix H6 were investigated. Interestingly, helix H6
conformation of the VDR in complex with TTYN are all similar to
that with 1,25(OH)2D3, rather than that with CD4802, one of CDs
(Fig. S4A and S4B). Therefore, this result indicated that the
AH12
H7
H6
H10
VDR LBD
Similar ligand efficacy Distinct ligand potency
TTYN-8
H3
H5
B
1,25(OH)2D3
Ser233
Arg270
Ser271
His301
His393
Fig. 4. Effects of TTYN–LBD interactions on VDR-mediated transcription. (A) Effects of mutations of TTYN-interacting residues within the hVDR LBD on receptor function.
HEK293 transfected with wild-type (WT) or each mutant hVDR was treated with 1,25(OH)2D3 (black), TTYN-7 (yellow), TTYN-8 (orange), TTYN-11 (green), and TTYN-12
(magenta) at estimated EC50 concentrations, as indicated in Fig. 1C. Residue numbers in rVDR are shown in parentheses. (B) Schematic model of VDR agonism by TTYNs. The
ligand efﬁcacy is commonly regulated by the formation of a hydrogen-bond network around H6–H7 loop and helix H10 (red region and line). On the other hand, potency
relies on the formation of ta hydrogen-bond network between helices H3 and H5 (blue region and line) and the rearrangement of the intramolecular interaction between
helices H5 and H7 (orange region and line) in a ligand-speciﬁc manner.
962 L. Asano et al. / FEBS Letters 587 (2013) 957–963structural alteration of helix H6 does not always induced by non-
secosteroidal ligands for VDR activation.
4. Conclusion
The present study revealed that ligand potency and efﬁcacy for
VDR-mediated transcription are regulated through ligand-speciﬁc
hydrogen-bond networks involving several helices. We propose a
structural model of VDR agonism that depends upon the formation
and rearrangement of hydrogen-bond networks in a ligand-speciﬁc
manner (Fig. 4B, see the ﬁgure legend for details). These ﬁndings
may be useful for the rational design of new non-calcemic VDR-
targeting drugs.
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